🇺🇸 FDA

Intelligence · Clinical Pipeline

IONIS PHARMACEUTICALS Pipeline

All ClinicalTrials.gov programs at IONIS PHARMACEUTICALS — phase, modality, and trial IDs.

Programs
33

Quick answer

IONIS PHARMACEUTICALS has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  2. Donidalorsen

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    4 trials

  3. Donidalorsen

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  4. Eplontersen

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

    phase 3 small molecule active

    2 trials

  5. Eplontersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  6. ION 682884, ION 682884

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  7. ION 682884, Placebo injection, 0.8 ml (is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in Water for Injection) for subcutaneous administration

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

    phase 3 small molecule active

    1 trial

  8. ION363

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  9. ION363, ION363, Artificial Cerebrospinal Fluid (aCSF) for Injection, 5.0 mL (Placebo)

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations

    phase 3 small molecule active

    1 trial

  10. ION582

    IONIS PHARMACEUTICALS INC

    Angelman Syndrome

    phase 3 small molecule active

    2 trials

  11. ION582

    IONIS PHARMACEUTICALS INC

    Angelman syndrome

    phase 3 small molecule active

    1 trial

  12. ISIS 3521

    IONIS PHARMACEUTICALS INC

    Lung Cancer

    phase 3 mab completed

    1 trial

  13. ISIS 678354

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    1 trial

  14. ISIS 678354, ISIS 678354, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  15. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  16. ISIS 721744, ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  17. Inotersen

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule completed

    1 trial

  18. Inotersen

    IONIS PHARMACEUTICALS INC

    FAP

    phase 3 small molecule completed

    2 trials

  19. Mipomersen

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  20. Mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  21. Olezarsen

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia

    phase 3 small molecule completed

    3 trials

  22. Olezarsen

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 3 small molecule completed

    2 trials

  23. Olezarsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    3 trials

  24. Placebo injection, 0.8 ml is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in water for injection (wfi) intended for subcutaneous injection, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia.

    phase 3 small molecule active

    1 trial

  25. Tofersen

    IONIS PHARMACEUTICALS INC

    ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

    phase 3 small molecule completed

    1 trial

  26. Tofersen

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  27. Volanesorsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule completed

    2 trials

  28. Volanesorsen

    IONIS PHARMACEUTICALS INC

    Hypertriglyceridemia

    phase 3 small molecule completed

    1 trial

  29. mipomersen

    IONIS PHARMACEUTICALS INC

    Lipid Metabolism, Inborn Errors

    phase 3 small molecule completed

    2 trials

  30. mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Lipid Metabolism, Inborn Errors

    phase 3 small molecule completed

    2 trials

  31. mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  32. volanesorsen

    IONIS PHARMACEUTICALS INC

    Familial Partial Lipodystrophy

    phase 3 small molecule terminated

    1 trial

  33. zilganersen

    IONIS PHARMACEUTICALS INC

    Alexander Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does IONIS PHARMACEUTICALS have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.